贵州益佰制药股份有限公司 2025年第三季度报告

Core Viewpoint - The company has announced its third-quarter financial report for 2025, detailing significant corporate actions including a capital increase for its subsidiary and a planned acquisition of minority shares [3][8][19]. Financial Data - The financial report for the third quarter of 2025 has not been audited [3][10]. - The company reported a capital increase for its subsidiary, Guizhou Yibai Traditional Chinese Medicine Formula Granules Co., Ltd., from RMB 20 million to RMB 199.85 million, with the company holding 59.97% of the shares post-increase [6][8]. Shareholder Information - As of September 30, 2025, the company has a repurchase account holding 7,533,500 shares, which is not included in the top ten shareholders [4]. - The company plans to acquire the remaining 40.03% of shares in its subsidiary from Guizhou Agricultural Development Fund for RMB 80 million [8][9]. Board Meeting - The eighth board meeting on October 28, 2025, approved the third-quarter report and several governance-related proposals, including the establishment and revision of various internal management systems [19][20][21]. - All board members were present, and the meeting adhered to legal and procedural requirements [18][19]. Corporate Governance - The board approved revisions to multiple governance documents, including the management of directors and senior executives, internal control systems, and investor relations management [20][22][24]. - The governance changes aim to enhance the company's governance structure in compliance with relevant laws and regulations [20].